Studies on colorectal cancer [153] and nasopharyngeal carcinoma [148] have shown that the level of CXCL16 expression is associated with tumor infiltration by anti-cancer TIL, and so CXCL16 can be used in cancer therapy. This evidence concerns the gene CXCL16 and nasopharyngeal carcinoma.